ReviewCancer imaging : the official publication of the International Cancer Imaging Society2026
NI-RADS in posttreatment head and neck cancer surveillance: a framework for standardized imaging with clinical impact.
Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Neck Imaging Reporting and Data System (NI-RADS), developed through the American College of Radiology (ACR), provides a standardized framework for interpreting and managing posttreatment imaging in head and neck cancer. Building upon the success of NI-RADS PET/CT, the recently released NI-RADS MRI version 2025 represents a major advancement, introducing modality-specific descriptors and management recommendations tailored to MRI. This review summarizes the history and development of NI-RADS, highlighting both the validated PET/CT framework and the subsequent MRI update. At its core, NI-RADS offers a standardized lexicon for post-treatment findings, a structured reporting format that stratifies risk of disease recurrence, and linked management recommendations. Surveillance imaging is an essential component of post-treatment head and neck cancer care. Evidence strongly supports early imaging surveillance within six months of definitive therapy, whereas the benefits of long-term imaging surveillance remain under-investigated. With the goal of improving patient outcomes, NI-RADS provides a consistent, risk-adaptable framework that supports both clinical decision-making and standardized data collection for future outcomes research. NI-RADS will continue to evolve with advances in oncologic management and imaging technology. Future updates may incorporate ultrasound, advanced imaging techniques, and circulating tumor biomarkers. As surveillance strategies in head and neck cancer advance, NI-RADS is well positioned to serve as the foundation for personalized, risk-based imaging surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.